Market closedADR
Immunocore/$IMCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunocore
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Ticker
$IMCR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
493
Website
Immunocore Metrics
BasicAdvanced
$1.5B
-
-$1.02
0.80
-
Price and volume
Market cap
$1.5B
Beta
0.8
52-week high
$66.00
52-week low
$27.69
Average daily volume
196K
Financial strength
Current ratio
4.382
Quick ratio
4.258
Long term debt to equity
119.533
Total debt to equity
119.962
Interest coverage (TTM)
-2.78%
Management effectiveness
Return on assets (TTM)
-4.08%
Return on equity (TTM)
-14.00%
Valuation
Price to revenue (TTM)
4.674
Price to book
4.02
Price to tangible book (TTM)
4.02
Price to free cash flow (TTM)
69.406
Growth
Revenue change (TTM)
24.37%
Earnings per share change (TTM)
-9.63%
3-year revenue growth (CAGR)
104.10%
3-year earnings per share growth (CAGR)
-37.75%
What the Analysts think about Immunocore
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Immunocore Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Immunocore Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Immunocore News
AllArticlesVideos
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
GlobeNewsWire·1 day ago
Immunocore to present at upcoming investor conferences
GlobeNewsWire·1 week ago
Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Immunocore stock?
Immunocore (IMCR) has a market cap of $1.5B as of March 12, 2025.
What is the P/E ratio for Immunocore stock?
The price to earnings (P/E) ratio for Immunocore (IMCR) stock is 0 as of March 12, 2025.
Does Immunocore stock pay dividends?
No, Immunocore (IMCR) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next Immunocore dividend payment date?
Immunocore (IMCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunocore?
Immunocore (IMCR) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.